By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics has reported a 134 percent increase in its fourth-quarter revenues, driven by sales of its ResponseDx line of pharmacogenomic tests.

The Los Angeles-based firm brought in total revenues of $3.4 million for the three-month period ended Dec. 31 compared to $1.4 million for the fourth quarter of 2008. The company cited a ramp up in sales of its ResponseDx tests, with revenues growing 81 percent compared to the third quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.